Miller School of Medicine >> UM Innovation >> Technology Transfer >> For Industry
 
Neurology
ID# TT-179
More Details
Contact
Technology Repair and Regeneration for Spinal Cord Injury
Scientific Relevance This invention is a novel three component combination therapy which entails 1) the use of specialized nerve growth promoter cells in a bridge-like manner grown from the patient's own cells (Schwann cell bridge), 2) a class of drugs to reduce the inhibition to heal (phosphodiesterase inhibitors) and 3) a specific protein activator (cyclic adenosine monophosphate, cAMP).
Commercial Opportunity In an average year, there are greater than 11,000 spinal cord injuries (SCI) in the U.S. About 40% occur in motor vehicle accidents and 25% result from violent encounters.  Approximately 250,000 - 400,000 people in the U.S. are paralyzed as a result of SCI. The economic impact is estimated at $9.7 billion each year and the cost of treating pressure sores alone is estimated at $1.2 billion. A therapeutic approach to a cure or an improvement would have an enormous socio-economic impact.
Competitive Advantage This is the only treatment that uses the patient’s own cells to regenerate the central nervous system.  The combination of cells and bioactive agents is unique and together they bridge the gap of the injury and facilitate directional nerve growth.
Inventors Mary Bunge and Damian Pearse
ID# UMF-31
More Details
Contact
Technology Transgenic Mice Expressing A Real-Time Reporter For Cellular Camp In A Tissue-Selective And Inducible Manner
Scientific Revelance Cyclic AMP (cAMP) mediates the response to hormones, neurotransmitters and other molecules in practically every tissue of the body.  The inventors have generated a unique transgenic mouse that is able to express an inducible fluorescent cAMP reporter in targeted cells and tissues.  To achieve this, transgenic mice carrying the newly generated and unique cAMP reporter are mated with mice carrying an appropriate, tissue-specific, antibiotic-sensitive triggering mechanism in their genome.  Mice tailored to a specific tissue can be readily generated. By injecting a commonly available antibiotic, researchers can then induce the synthesis of the cAMP reporter in pre-specified cells.  Using this mouse model, cAMP can be examined in intact organs, tissues and cells both in vitro and in vivo. The transgenic mouse will make it possible to monitor how intracellular cAMP levels change in response to metabolites, transmitters, hormones, and drugs in real time and with high spatial resolution (i.e., single cells and even subcellular regions). 
Commercial Opportunity This mouse is an important drug discovery tool.  Pharmaceutical industry scientists as well as academic researches can use this mouse to monitor responses to existing drugs and develop new ones. Additionally, this mouse could be used to test the effects of treatments affecting the brain, spinal cord, or autonomic nervous system.
Competitve Advantage This only mouse model available that allows responses to drugs, metabolites, transmitters, hormones, pharmaceuticals, etc. to be monitored visually in vivo.   Furthermore, the response can be seen in real time with high spatial resolution.
Inventors Nirupa Chaudhari, and Stephen D. Roper
 

Copyright © 1997-2008
University of Miami,
All Rights Reserved.

Terms of Use
Privacy Statement
Contact Us
Medical Disclaimer
Site Map
Web Technology